Søren Weis Dahl
Directeur/Membre du Conseil chez PILA PHARMA AB
Profil
Søren Weis Dahl is currently the Chief Executive Officer & Director at Deck Therapeutics, Inc. and a Director at Pila Pharma AB.
He was previously the Chief Executive Officer at Prophylix AS from 2015 to 2019.
Dahl holds an MBA from Copenhagen Business School, a doctorate from the Technical University of Denmark, and a graduate degree from the same institution.
Postes actifs de Søren Weis Dahl
Sociétés | Poste | Début |
---|---|---|
PILA PHARMA AB | Directeur/Membre du Conseil | 30/05/2023 |
Deck Therapeutics, Inc.
Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deck Therapeutics, Inc. is an American acute omega-3 fatty acid therapeutics development company. Søren Weis Dahl has been the CEO of the company since 2020. | Directeur Général | 01/01/2014 |
Anciens postes connus de Søren Weis Dahl
Sociétés | Poste | Fin |
---|---|---|
Prophylix AS
Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Directeur Général | 01/01/2019 |
Formation de Søren Weis Dahl
Technical University of Denmark | Graduate Degree |
Copenhagen Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
PILA PHARMA AB | Health Technology |
Entreprise privées | 2 |
---|---|
Prophylix AS
Prophylix AS Pharmaceuticals: MajorHealth Technology Prophylix AS operates as biotech company that offers orphan drug programs and follow-on therapy. The firm develops a prophylactic medicinal product to prevent newborns from Foetal/Neonatal Alloimmune Thrombocytopenia (FNAIT). The company was founded by Bjørn Ragnar Skogen, Jens Kjeldsen-Kragh, Anne Husebekk, and Mette Kjaer in 2008 and is headquartered in Tromso, Norway. | Health Technology |
Deck Therapeutics, Inc.
Deck Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Deck Therapeutics, Inc. is an American acute omega-3 fatty acid therapeutics development company. Søren Weis Dahl has been the CEO of the company since 2020. | Health Technology |